Topical Cholesterol and Statin Therapy for Porokeratosis: A Systematic Review and Exploratory Meta‐Analysis
Authors:
- Maryam SajjadMSMaryam Sajjad
- Leena AlotaibiLALeena Alotaibi
- Ahmed N. AlqefariAAAhmed N. Alqefari
- Norah AljabrNANorah Aljabr
- Ahad Abdulaziz AlruhaymiAAAhad Abdulaziz Alruhaymi
- Turki Saeed AlkahtaniTATurki Saeed Alkahtani
- Ahmed Ayed N. AlanaziAAAhmed Ayed N. Alanazi
- Naif Abed AlshamariNANaif Abed Alshamari
- Aliyah Abdulmohsen AlabdulqaderAAAliyah Abdulmohsen Alabdulqader
- Alanoud Abdullah Al DaejADAlanoud Abdullah Al Daej
- Zain AbbaraZAZain Abbara
Open Access
- 1 January 2026
- journal article
- review article
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 3648230
Abstract
Background: Porokeratosis comprises a group of clinically diverse keratinization disorders unified by the cornoid lamella and increasingly understood through alterations in the mevalonate/cholesterol biosynthesis pathway, including germline variants, somatic second‐hit events, clonal mosaicism, and emerging epigenetic mechanisms. These biological insights support investigation of pathogenesis‐directed topical statin‐based therapy, with or without cholesterol supplementation. Aim: This systematic review evaluated the reported clinical improvement, safety, and comparative evidence of topical cholesterol/statin combination therapy versus topical statin monotherapy for porokeratosis. Methods: PubMed, Scopus, Web of Science, and Cochrane Library were searched through January 2026. Two independent reviewers screened studies and extracted data on study design, porokeratosis subtype, treatment formulation, clinical outcomes, and adverse events. Because the evidence base consisted largely of small uncontrolled reports with heterogeneous outcome definitions, quantitative summaries were considered exploratory and were interpreted cautiously. Results: Thirteen studies including 89 patients were included. Most studies were case reports or case series, with limited controlled evidence. Published uncontrolled reports generally described clinical improvement after topical cholesterol/statin therapy, including improvement in erythema and lesion morphology; however, these findings are subject to substantial selection, reporting, and publication bias. Safety data suggested that adverse events were usually mild and local, including application‐site discomfort, transient pruritus, erythema, dryness, or eczematous reactions. In the available controlled studies comparing combination therapy with topical statin monotherapy, no statistically significant difference was detected in clinical improvement or severity‐score change, although confidence intervals were wide and the analyses were underpowered. Conclusion: Topical cholesterol/statin therapy remains a biologically plausible and clinically promising approach for porokeratosis, but larger standardized randomized trials are required to define its comparative effectiveness, optimal formulation, and long‐term safety.Keywords
This publication has 39 references indexed in Scilit:
- Safety and efficacy of topical simvastatin plus cholesterol cream versus topical simvastatin cream alone for porokeratosis ptychotropica: A randomized, single-blind, split-body, placebo-controlled, investigator-initiated trialJournal of the American Academy of Dermatology, 2025
- Gene-specific somatic epigenetic mosaicism of FDFT1 underlies a non-hereditary localized form of porokeratosisThe American Journal of Human Genetics, 2024
- Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for the Treatment of Disseminated Superficial Actinic PorokeratosisJAMA Dermatology, 2023
- A rare case of punctate porokeratosis treated with topical lovastatin/cholesterolJAAD Case Reports, 2023
- Two percent lovastatin ointment as a pathogenesis-directed monotherapy for porokeratosisJAAD Case Reports, 2020
- Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapyJournal of the American Academy of Dermatology, 2020
- Permeability and microstructure of cholesterol-depleted skin lipid membranes and human stratum corneumJournal of Colloid and Interface Science, 2019
- Metabolic Induction of Trained Immunity through the Mevalonate PathwayCell, 2018
- Cochrane Handbook for Systematic Reviews of Interventions2008
- Porokeratosis large skin lesions are susceptible to skin cancer development: histological and cytological explanation for the susceptibilityJournal of Cancer Research and Clinical Oncology, 1993